02487 CUTIA-B
- 5.680
- -0.070-1.22%
CUTIA-B News
CUTIA-B (02487.HK): Consumer & R&D dual-driven pan-skin platform, new star strength can be expected
CICC: Reaffirmed the "outperform" rating for Sea Ltd (02487), with the target price raised to HK$15.2.
Cordi-B (02487.HK): Skincare growth exceeded expectations, accounting for nearly half, and the progress of anesthetic cream exceeded expectations, and the market progressed the fastest commercialization & pipeline progress on a dual track
CICC: Maintains outperform rating for KeDuoB(B02487), target price lowered to HKD 11.
Cordi-B (02487.HK): The online listing application for table hemp tubes was accepted, and the repurchase showed the company's confidence
Fangzheng Securities: Liding Double Lidocaine Ointment's listing application has been accepted. Maintain a 'recommended' rating for Kodis-B (02487).
Cordi-B (02487.HK): The progress of acceptance of the marketing application for lidine biscaine anesthetic cream exceeded market expectations
Cordi-B (02487.HK): The listing application for lidine dual caine anesthetic cream was accepted, showing confidence to repurchase shares
Cordi-B (02487.HK): The hair and skin care product line started quickly and progressed smoothly in the research pipeline
Cordi-B (02487.HK) Hong Kong Stock Company Information Update Report: 2023 Revenue Exceeds Expectations and the R&D Pipeline Is Expected to Be Implemented to Contribute to Growth
Kodi B (02487.HK) commercialized as an innovative sail paddle and became a leading pan-dermatology platform enterprise
CITIC Lyon: Maintaining Kodi Group's (02487) “Buy” Rating Target Price Reduction 77% to HK$8.8
Cordi-B (2487.HK): Deepening R&D and Consumption Barriers to Build a Leading Integrated Dermatology Platform
Cordi-B (02487.HK): Forecasts revenue of about 138 million yuan in 23, and commercialization progress exceeded expectations
Cordi-B (02487.HK) Company Review Report: Continued Explosion of Commercialization Drives Revenue Exceeding Expectations, Heavy Pipeline to be Launched in 25 Years
Kodi B (02487.HK): Strong commercialization helps the off-season not fade & double 11 promotion continues to increase, and deep reserves on the R&D side are expected to be poised to go
Kodi B (02487.HK) First Coverage Report: R&D Drives Commercialization Orients Pan-Dermatology Market Upstart
Cordy-B (02487.HK): Commercialization starts smoothly and clinical product development is progressing steadily
Kodi (2487.HK): Smooth commercialization process boosts revenue growth, September entry is expected to further increase liquidity
Cordy-B (02487.HK) focuses on the needs of pan-dermatology to create a diverse product portfolio
No Data
